Brief: Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated With NMRA-215 In Preclinical Diet-Induced Obesity Model
27/10/2025 10:32
Oct 27 (Reuters) - Neumora Therapeutics Inc NMRA.O: NEUMORA THERAPEUTICS ANNOUNCES CLASS-LEADING WEIGHT LOSS DEMONSTRATED WITH NMRA-215 IN PRECLINICAL DIET-INDUCED OBESITY MODEL NEUMORA THERAPEUTICS INC - NMRA-215 SHOWS 19% WEIGHT LOSS AS MONOTHERAPY NEUMORA THERAPEUTICS INC - TO START PHASE 1 STUDY IN Q1 2026 NEUMORA THERAPEUTICS INC - NMRA-215 SHOWS 26% WEIGHT LOSS WITH SEMAGLUTIDE Source text: ID:nGNX4TxZVv Further company coverage: NMRA.O
Recent news on Neumora Therapeutics
See all newsNeumora Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Neumora Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update
Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex